Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database

Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database

Background: Biologics play an important role in the treatment of moderate to severe Crohn’s disease (CD). Ustekinumab was approved for such patients in the Republic of Korea on 1 December 2018. Therefore, we need to compare the efficacy of ustekinumab and anti-TNF inhibitors. Methods: We compared on...

Full description

Bibliographic Details
Main Authors:	Gi Hyeon Seo, Sung Hoon Jung
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	Journal of Clinical Medicine
Subjects:	persistence Crohn’s disease ustekinumab
Online Access:	https://www.mdpi.com/2077-0383/12/6/2397

Similar Items

Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease
by: Cristina Suárez Ferrer, et al.
Published: (2024-01-01)

Clinical utility of ustekinumab in Crohn’s disease
by: Kotze PG, et al.
Published: (2018-02-01)

Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort studyResearch in context
by: Hongsheng Yang, et al.
Published: (2023-12-01)

Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
by: Kyunghwan Oh, et al.
Published: (2023-01-01)

The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial
by: Rintaro Moroi, et al.
Published: (2023-11-01)

High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab
by: Laura Doornekamp, et al.
Published: (2020-08-01)

Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn’s disease
by: Klaudia Miklusiak, et al.
Published: (2023-05-01)

Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
by: Sadik Saman, et al.
Published: (2019-07-01)

Response to Ustekinumab Therapy Is Associated with an Improvement of Nutritional Status in Patients with Crohn’s Disease
by: Lorenzo Bertani, et al.
Published: (2023-09-01)

USTEKINUMAB IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY
by: Paula Cenira Senger de CASTRO, et al.
Published: (2022-11-01)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
by: Amanda Hansson-Hedblom, et al.
Published: (2018-08-01)

Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
by: Avantika Mishra, et al.
Published: (2018-08-01)

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
by: María Chaparro, et al.
Published: (2022-08-01)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
by: Rayer Cassandra, et al.
Published: (2022-12-01)

A bibliometric and visual analysis of the use of ustekinumab in Crohn’s disease using CiteSpace
by: Yi Chen, et al.
Published: (2024-01-01)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
by: Matsumoto S, et al.
Published: (2018-07-01)

Ustekinumab in pediatric patients with Crohn’s disease: safety, and efficacy results from a multicenter retrospective study in China
by: Ping Li, et al.
Published: (2024-04-01)

Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumab [version 2; peer review: 2 approved]
by: Georgios Axiaris, et al.
Published: (2023-10-01)

Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn’s Diseasesummary
by: Anna-Maria Globig, et al.
Published: (2021-01-01)

Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease
by: Manrong He, et al.
Published: (2021-12-01)

Ustekinumab in patients with Crohn’s disease with extraintestinal manifestations (psoriasis)
by: P. A. Makarchuk, et al.
Published: (2020-10-01)

Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy
by: Roberto Ravasio, et al.
Published: (2023-01-01)

Ankilozan Spondilit, Crohn Hastalığı ve Anti-tümör Nekroz Faktör-alfa Tedavi ile İndüklenen Psoriasis olan Hastada Ustekinumab Tedavisine Dramatik Yanıt
by: Sevilay Kılıç, et al.
Published: (2020-12-01)

Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease
by: Jiayin Yao, et al.
Published: (2023-07-01)

Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil
by: Julio Maria Fonseca Chebli, et al.
Published: (2022-10-01)

Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn’s Disease: A Retrospective Real-World Analysis
by: Jiayin Yao, et al.
Published: (2023-01-01)

Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn’s Disease
by: Luisa Bertin, et al.
Published: (2024-03-01)

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
by: Toshifumi Hibi, et al.
Published: (2017-10-01)

New Possibilities for the Treatment of Crohn’s Disease
by: Z. A. Mamieva, et al.
Published: (2019-12-01)

Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
by: Cristina Rubín de Célix, et al.
Published: (2022-07-01)

Real clinical practice of complicated Crohn’s disease treatment with ustekinumab: clinical case presentation
by: P. A. Makarchuk, et al.
Published: (2022-05-01)

Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report
by: Artsiom Klimko, et al.
Published: (2024-01-01)

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
by: Michelle Vu, et al.
Published: (2023-03-01)

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
by: Ahmad Albshesh, et al.
Published: (2023-03-01)

Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use
by: Marleen Bouhuys, et al.
Published: (2023-09-01)

Clinical Advances in Ustekinumab in the Treatment of Crohn's Disease
by: Xin ZHAO, Yingde WANG
Published: (2022-09-01)

Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
by: Jauregui-Amezaga A, et al.
Published: (2017-11-01)

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease
by: Xavier Roblin, et al.
Published: (2023-05-01)

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study
by: Rogério Serafim Parra, et al.
Published: (2022-04-01)

Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study
by: Lingya Yao, et al.
Published: (2021-11-01)